Garin A M, Tiuliandin S A, Sokolov A V, Figurin K M, Patiutko Iu I, Polotskiĭ B E
Vestn Ross Akad Med Nauk. 1995(4):33-7.
The treatment of testicular cancer has undergone considerable evolution since the introduction of cisplatin and widespread recognition of its curative potentials at any stages of disease. This article provides an overview on statistical and epidemiological information, the latest developments in testicular cancer biology. Also, the results of treating 360 patients with nonseminomatous and 97 patients with seminomatous germ cell tumors are presented. A combined chemotherapy with cisplatin, etoposide and bleomycin demonstrates the highest rate of activity in nonseminomatous germ cell tumor patients. Surgical resection of residual masses after chemotherapy continues to be an important component of combined modality therapy in nonseminomatous testicular tumors. The needs for regular clinical examination during a follow-up have been underlined.
自从顺铂被引入且其在疾病任何阶段的治愈潜力得到广泛认可以来,睾丸癌的治疗已经经历了相当大的演变。本文概述了统计和流行病学信息、睾丸癌生物学的最新进展。此外,还介绍了360例非精原细胞瘤患者和97例精原细胞瘤患者的治疗结果。顺铂、依托泊苷和博来霉素联合化疗在非精原细胞瘤患者中显示出最高的活性率。化疗后残留肿块的手术切除仍然是非精原性睾丸肿瘤综合治疗的重要组成部分。强调了随访期间定期临床检查的必要性。